Table 1 Registered and potential indications of recombinant activated factor VII in patients undergoing abdominal surgery
Registered indications | Prophylaxis of bleeding related to surgical or invasive interventions as well as treatment of bleeding in patients with |
-Congenital hemophilia A or B if inhibitors are present (>5 Bethesda units) or if a strong increase of inhibitors must be expected upon administration of factor VIII or IX [41] | |
- Acquired hemophilia [42] | |
- Congenital factor VII deficiency [43] | |
- Glanzmann thrombasthenia with antibodies to glycoprotein IIb/IIIa and/or human leucocyte antigen and presence or history of refractoriness to platelet concentrates [44] | |
Potential indications | Prophylaxis of surgical bleeding in patients with reduced activity or deficiency of coagulation factors, especially with specific inhibitors to plasmatic factors [45] and acquired von Willebrand disease [46] |
Treatment of bleedings after all conventional measures have failed in patients with | |
- Chronic liver disease [47] | |
- Thrombocytopathy [48] | |
- Platelet-refractory thrombopenia [49] | |
- Bleeding complications due to trauma or surgery in patients without any detectable systemic impairment of hemostasis (references in Tables 3 and 4) | |
- Drug-induced bleeding, especially by hirudine (in connection with supportive measures), danaparoid, fondaparinux, and glycoprotein IIb/IIIa inhibitors [50] |